How Was GHK-Cu Discovered?

GHK-Cu was discovered in the early 1970s by an American biochemist named Dr. Loren Pickart. His discovery marked the beginning of decades of scientific interest in this small copper-binding peptide.

At the time, Dr. Pickart was working on understanding how the human body repairs itself after injury. He was particularly focused on the processes involved in wound healing and tissue regeneration. His research led him to study human blood plasma — the liquid portion of blood that carries proteins, nutrients, and other important molecules throughout the body.

The Scientific Context in the 1970s

In the early 1970s, wound healing research was still in its early stages compared to today. Scientists knew that certain proteins in the blood played important roles in healing, but they did not fully understand the specific mechanisms involved. Dr. Pickart was especially interested in a very common protein called albumin, which makes up a large part of the proteins found in human blood plasma.

While studying albumin, Dr. Pickart was trying to identify small fragments or molecules that might be involved in the body’s natural repair processes. During his laboratory work, he isolated a very small chain made up of just three amino acids: glycine, histidine, and lysine. This short chain is known as the tripeptide GHK.

The Key Discovery: Binding with Copper

What made this finding particularly interesting was that the GHK molecule had a strong natural ability to bind to copper. Copper is an essential trace mineral that the body uses in many important processes, including the function of certain enzymes and the formation of connective tissue.

When the GHK tripeptide binds to copper, it forms a stable compound known as GHK-Cu (also called glycyl-L-histidyl-L-lysine copper). Dr. Pickart observed that this copper-bound form of the peptide appeared to have interesting effects in laboratory experiments. In early cell culture studies, GHK-Cu seemed to influence how certain cells behaved, particularly in processes related to tissue maintenance and repair.

This observation was the starting point for what would become decades of research into GHK-Cu.

Dr. Loren Pickart’s Lifelong Work

Dr. Loren Pickart dedicated most of his scientific career to studying GHK-Cu. After his initial discovery, he continued researching the peptide for more than 40 years. He published numerous scientific papers and became widely recognized as one of the leading experts on this molecule.

Throughout his career, Dr. Pickart worked at several research institutions, including the University of Washington and the University of California. He remained actively involved in GHK-Cu research until his passing in 2018. His work helped lay the foundation for the many laboratory and animal studies that followed.

How Research on GHK-Cu Developed Over Time

After the initial discovery in the 1970s, research on GHK-Cu gradually expanded:

• In the 1980s and 1990s, more scientists began studying the peptide in laboratory settings. Researchers conducted experiments using cell cultures to better understand how GHK-Cu interacts with cells.
• Later, some studies moved into animal models to observe the effects of GHK-Cu in living organisms.
• Over the following decades, hundreds of scientific papers were published exploring different aspects of the molecule, including its potential roles in skin biology, inflammation, and tissue remodeling.

Most of this research remained focused on basic science rather than direct medical applications. The majority of studies were conducted in controlled laboratory environments or using animal models.

Current State of Knowledge

Today, GHK-Cu continues to be studied in scientific laboratories around the world. However, it is important to understand the current limitations of the research:

• The vast majority of studies on GHK-Cu have been conducted in cell cultures or animal models.
• There is still only a limited amount of high-quality human clinical research available.
• No large-scale, long-term human studies have been completed to fully evaluate its safety or effects in people.
• GHK-Cu is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for any medical or cosmetic use in humans.

Because of these limitations, researchers are still working to understand the full biological role of GHK-Cu and whether its effects observed in laboratory and animal studies can be translated to humans.

Summary

GHK-Cu was discovered in the early 1970s by Dr. Loren Pickart while he was studying human blood plasma and the body’s natural wound healing processes. During his research on the protein albumin, he isolated a small tripeptide (GHK) that had the ability to bind to copper, forming what we now know as GHK-Cu.

What began as a laboratory observation more than 50 years ago has led to decades of scientific research exploring the properties of this copper peptide. While laboratory and animal studies have provided interesting insights, much more research — particularly high-quality human clinical studies — is still needed.

This website does not provide medical advice.

All information on this page is for educational and research purposes only. GHK-Cu is an experimental research peptide and is not approved for human use by the FDA or EMA.